Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

  • End date
    Jul 21, 2025
  • participants needed
  • sponsor
    Third Affiliated Hospital, Sun Yat-Sen University
Updated on 21 January 2021
body mass index
type 2 diabetes mellitus
hemoglobin a1c
glycosylated hemoglobin
diabetic retinopathy


Diabetic retinopathy (DR) is an important cause of blindness.


Diabetic retinopathy (DR) is an important cause of blindness, and its development of an irreversible process. DR is not only the overall progress and the level of blood sugar, and blood glucose fluctuations more closely, is the key to a smooth hypoglycemic delay DR progression.Diabetes control and complication trail(DCCT) study shows that even though glycemic control was no significant difference in blood glucose fluctuations ,DR also have a significant difference. In this study, three different glucose-lowering program for: (A) a single oral anti-diabetic drugs, (B) basal insulin and oral anti-diabetic drugs, (C) premixed insulin and oral anti-diabetic drugs for comparison. Focus on the stability and the impact of these three programs hypoglycemic long-term prognosis of the DR, and thus affect the molecular mechanisms of DR-based exploration of glucose fluctuations, to optimize blood glucose solutions, lower blood sugar steady, slow progression of DR ultimate clinical purposes.

The multi-center study is to cooperate, enrolled 600 cases of type 2 diabetes, observe the effects of different solutions on blood sugar glucose fluctuations and retinopathy, a total of 5 years of follow-up. This will be the first at home and abroad to compare the incidence of hypoglycemic effect programs on DR large multi-center, randomized, controlled clinical studies, clinical practice will optimize the treatment of type 2 diabetes theoretical and evidence-based medicine.

Condition Diabetic Retinopathy, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Macular Edema
Treatment Metformin, Lantus, Novomix30
Clinical Study IdentifierNCT02587741
SponsorThird Affiliated Hospital, Sun Yat-Sen University
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

aged 30-65
# 2\. diagnosed to be type 2 diabetes in accordance with the WHO diagnostic
criteria in 1999
\. diabetes duration for 5 years or less
\. the glycosylated hemoglobin (HbA1c) is higher than or equal to7.0%
\. body mass index (BMI) 20-35 kg/m2
\. fluorescein fundus angiography (FFA) showed no diabetic retinopathy
\. women of childbearing-age have birth control plan for 5 years plan

Exclusion Criteria

pregnant or lactating women
diabetes autoantibodies (GAD) antibodies positive
occurred state of diabetic ketoacidosis, diabetes, high permeability, diabetes lactic acidosis within a half years
aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 times higher than normal ceiling, and/or serum creatinine (Cr) or 133 umol/l (1.5 mg/dl)
hemoglobin disease history which can affect determination of HbA1c
have received a coronary angioplasty, coronary artery stent implantation, coronary artery bypass surgery, there was myocardial infarction, unstable angina, and clinical significance of abnormal ecg, cerebrovascular accident, or transient ischemic attack
psychiatric patients
any eye eyesight < 0.1 patients (WHO blind eye disease: keratitis, need serious cataract surgery, glaucoma, uveitis, high myopia shaft > 26.5 mm, history of ocular trauma;Other ophthalmology medical history: the central vein occlusion, branch vein occlusion, wet sex senile macular degeneration, etc
in eye surgery history, history of cataract surgery, and three months; Other serious diseases, the researchers think that don't fit into the patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note